Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia

Current Pharmaceutical Design

Volumn 20, Issue 2, 2014, Pages 161-171

  Stasiak, Anna ^a   Mussur, Mirosław ^a   Unzeta, Mercedes ^b   Samadi, Abdelouahid ^c   Marco Contelles, José L ^c   Fogel, W Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

^c INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Brain biogenic amines' concentration; Monoamine oxidases' inhibition; Permanent bilateral occlusion of the common carotid arteries; Vascular dementia

Indexed keywords

AMINE; AMINE OXIDASE (FLAVIN CONTAINING); ASS 188; ASS 234; CHOLINESTERASE; DONEPEZIL; DOPAMINE; HISTAMINE; HISTAMINE METHYLTRANSFERASE; MONOAMINE OXIDASE INHIBITOR; N [(5 BENZYLOXY 1 METHYL 1H INDOL 2 YL)METHYL] N METHYLPROP 2 YN 1 AMINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN; COMMON CAROTID ARTERY; IN VIVO STUDY; MEMORY; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REFERENCE MEMORY; WORKING MEMORY;

ACETYLCHOLINESTERASE; ANIMALS; BIOGENIC MONOAMINES; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; INDOLES; MALE; MEMORY; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84892952719     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990026     Document Type: Article

References (62)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-52.
2. Diaz NL, Waters CH. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev Neurother 2009; 9: 1781-9.
3. Ishunina TA, Kamphorst W, Swaab DF. Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia. J Neuropathol Exp Neurol 2004; 63: 1243-54.
4. Perez V, Unzeta M. PF 9601N [N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine], a new MAO-B inhibitor, attenuates MPTPinduced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem Int 2003; 42: 221-9.
5. Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 2007; 82: 297-325.
6. Gallagher DA, Schapira AH. Etiopathogenesis and treatment of Parkinson's disease. Curr Top Med Chem 2009; 9: 860-8.
7. Facecchia K, Fochesato LA, Ray SD, Stohs SJ, Pandey S. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol [serial on the Internet]. 2011 Jul 14; [cited 2012 May 25]; 683728: [12 pages]. Available from: http://www. ncbi. nlm. nih. gov/pmc/articles/PMC3139184/pdf/JT2011-683728. pdf.
8. Musia A, Bajda M, Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007; 14: 2654-79.
9. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15: 375-90.
10. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-47.
11. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295-309.
12. Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp Neurobiol 2011; 20: 1-17.
13. Weyler W, Hsu YP, Breakefield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 1990; 47: 391-417.
14. Shih JC, Chen K, Geha RM. Determination of regions important for monoamine oxidase (MAO) A and B substrate and inhibitor selectivities. J Neural Transm 1998; 52(Suppl): 1-8.
15. Talesa VN. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 2001; 122: 1961-9.
16. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergicserotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005; 43: 442-9.
17. Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008; 195: 30-8.
18. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
19. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994; 8: 744-51.
20. Massoulié J, Sussman J, Bon S, Silman I. Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res 1993; 98: 139-46.
21. Cumming P, Vincent SR. Inhibition of histamine-Nmethyltransferase (HNMT) by fragments of 9-amino-1, 2, 3, 4-tetrahydroacridine (tacrine) and by beta-carbolines. Biochem Pharmacol 1992; 44: 989-92.
22. Morisset S, Traiffort E, Schwartz JC. Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 1996; 315: R1-2.
23. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 2011; 32: 242-9.
24. Ishunina TA, Kamphorst W, Swaab DF. Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia. J Neuropathol Exp Neurol 2004; 63: 1243-54.
25. Stasiak A, Mussur M, Unzeta M, Lazewska D, Kiec-Kononowicz K, Fogel WA. The central histamine level in rat model of vascular dementia. J Physiol Pharmacol 2011; 62: 549-58.
26. Saura J, Luque JM, Cesura AM, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994; 62: 15-30.
27. Finali G, Piccirilli M, Oliani C, Piccinin GL. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 1991; 14: 523-36.
28. Riederer P, Danielczyk W, Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004; 25: 271-7.
29. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010; 626: 64-71.
30. Sanz E, Romera M, Bellik L, Marco JI, Unzeta M. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Med Sci Monit 2004; 10: BR477-84.
31. Hermanowicz N. Drug therapy for Parkinson's disease. Semin Neurol 2007; 27: 97-105.
32. Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 2007; 53: 214-22.
33. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl. 1983; 95: 57-80.
34. Lieberman A. Long-term experience with selegeline and levodopa in Parkinson's disease. Neurol 1992; 42(Suppl): 32-6.
35. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-22.
36. Cruces MA, Elorriaga C, Fernandez-Alvarez E. Acetylenic and allenic derivatives of 2-(5-benzyloxyindolyl) and 2-(5-hydroxyindolyl)methylamines: synthesis and in vitro evaluation as monoamine oxidase inhibitors. Eur J Med Chem 1991; 26: 33-41.
37. Cutillas B, Ambrosio S, Unzeta M. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci Lett 2002; 329: 165-8.
38. Pérez V, Marco JL, Fernández-Alvarez E, Unzeta M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAOB inhibition. Br J Pharmacol 1999; 127: 869-76.
39. Prat G, Pérez V, Rubi A, Casas M, Unzeta M. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPAinduced contralateral turning in 6-hydroxydopamine lesioned rats. J Neural Transm 2000; 107: 409-17.
40. Pérez V, Morón J, Pastó M, Unzeta M. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N. Neurobiology (Bp) 2000; 8: 231-6.
41. Sanz E, Quintana A, Battaglia V, et al. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J Neurochem 2008; 105: 2404-17.
42. Sanz E, Quintana A, Valente T, Manso Y, Hidalgo J, Unzeta M. Monoamine oxidase-B activity is not involved in the neuroinflammatory response elicited by a focal freeze brain injury. J Neurosci Res 2009; 87: 784-94.
43. Samadi A, Chioua M, Bolea I, et al. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem 2011; 46: 4665-8.
44. Samadi A, de Los Ríos C, Bolea I, et al. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur J Med Chem 2012; 52: 251-62.
45. Bolea I, Juárez-Jiménez J, de Los Ríos C, et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J Med Chem 2011; 54: 8251-70.
46. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev [serial on the Internet]. 2006 Jan 25; [cited 2012 Jul 4]; CD001190. Available from: http://onlinelibrary. wiley. com/doi/10. 1002/14651858. CD001190. p ub2/full.
47. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65.
48. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 2007; 54: 162-80.
49. Ni J, Ohta H, Matsumoto K, Watanabe H. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res 1994; 653: 231-6.
50. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A. Long-term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 2003; 30: 266-72.
51. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998; 112: 1199-208.
52. Taylor KM, Snyder SH. Isotopic microassay of histamine, histidine, histidine decarboxylase and histamine methyltransferase in brain tissue. J Neurochem 1972; 19: 1343-58.
53. Fowler CJ, Tipton KF. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. Neurochem 1982; 38: 733-6.
54. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. J Biol Chem 1951; 193: 265-75.
55. Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact 2008; 175: 222-6.
56. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002; 977: 513-22.
57. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev [serial on the Internet]. 2009 Jan 21; [cited 2012 May 25]; 1: CD004395. Available from: http://onlinelibrary. wiley. com/doi/10. 1002/14651858. CD004395. p ub2/full.
58. Bellik L, Dragoni S, Pessina F, Sanz E, Unzeta M, Valoti M. Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species. Acta Biochim Pol 2010; 57: 235-9.
59. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and Snitrosylation. Curr Drug Targets 2007; 8: 621-32.
60. Buccafusco JJ, Terry AV Jr. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 2000; 295: 438-46.
61. Youdim MB, Buccafusco JJ. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm 2005; 112: 519-37.
62. Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26: 27-35.